A bi-national, multicenter, double-blind, randomized study to evaluate the safety and tolerability of rasagiline mesylate in advanced Parkinson's disease (PD) patients with motor fluctuations treated with chronic levodopa/carbidopa therapy.

Trial Profile

A bi-national, multicenter, double-blind, randomized study to evaluate the safety and tolerability of rasagiline mesylate in advanced Parkinson's disease (PD) patients with motor fluctuations treated with chronic levodopa/carbidopa therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms PRESTO
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 08 Apr 2009 Actual patient number (254) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top